/
ECOR
$8.12+$0.28 (+3.57%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$65.0M
8M shares
52-week range
$4.16 – $10.50
63% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.98%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-9.71
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $993.0K | $2.4M | $3.5M | $5.5M | $8.6M | $16.0M | $25.2M | $32.0M |
| Cost of revenue | $578.7K | $1.2M | $1.7M | $1.4M | $1.6M | $2.8M | $3.8M | $4.2M |
| Gross profit | $414.2K | $1.2M | $1.8M | $4.1M | $7.0M | $13.2M | $21.4M | $27.8M |
| Gross margin | 41.7% | 51.6% | 50.3% | 74.6% | 81.2% | 82.5% | 85.0% | 86.8% |
| R&D | $12.5M | $9.9M | $4.2M | $2.5M | $5.5M | $5.3M | $2.4M | $2.7M |
| Operating income | −$54.6M | −$46.1M | −$24.7M | −$20.0M | −$22.9M | −$18.8M | −$12.2M | −$13.2M |
| EBITDA | −$54.5M | −$43.8M | −$23.9M | −$17.7M | −$22.0M | −$17.8M | −$10.7M | −$11.7M |
| Net income | −$55.8M | −$45.1M | −$23.5M | −$17.2M | −$22.2M | −$18.8M | −$11.9M | −$14.0M |
| Net margin | -5621.7% | -1888.8% | -672.5% | -315.9% | -257.9% | -117.5% | -47.2% | -43.6% |
| EPS (diluted) | -28.61 | -23.05 | -9.04 | -4.36 | -4.69 | -3.42 | -1.59 | -1.65 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $42M | $-1.50 | $-1.55–$-1.45 | 4 |
| 2027 | $54M | $-0.42 | $-0.48–$-0.37 | 3 |
| 2028 | $70M | $0.56 | $-0.14–$1.26 | 2 |
| 2029 | $75M | $0.36 | $0.35–$0.38 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
electroCore, Inc. Common Stock
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
www.electrocore.com- Employees
- 83
- IPO / List date
- Jun 22, 2018
- HQ
- ROCKAWAY, NJ
Held by traders on TradeandTell
No one on the platform currently holds ECOR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 44,409 | $267.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-02-15 | 1-for-15reverse |
| 2022-12-16 | 1.001-for-1 |
Recent trades on TradeandTell
No one on the platform has traded ECOR yet.
